1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations
| Autor: | Petrylak, D.P., Garmezy, B., Shen, J., Rezazadeh Kalebasty, A., Sartor, O., Dreicer, R., Agarwal, N., Hussain, M., Percent, I., Heath, E., Gedrich, R., Yu, T., Healey, D., Parameswaran, J., Sternberg, C.N., Gao, X. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S973-S974 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|